A novel approach that will shorten development times for new antibiotics has received over £1m of funding to scale up production and enter clinical trials.Procarta Biosystems, based on the UK’s Norwich Research Park, has been awarded two substantial EU grants to focus on ‘superbugs’ – MRSA, Clostridium difficile and the causative agent of tuberculosis.
Procarta’s patented approach is truly novel as it takes away the ability of the bacteria to control its own genes. This form of attack is completely new to bacteria and as gene expression is an essential process, it is difficult to see how bacteria could develop resistance to new drugs developed with this technology.
Dr Michael McArthur, co-founder and CSO of Procarta said the funding would help fast track the technology from lab to clinic.
“What is new to bacteria is also new to the pharmaceutical industry so in order to get serious backing the technology needs to prove itself,” he said.
“The science has been validated in the laboratory and we have previously secured public and private investment, however the EU grant will allow us to accelerate development of a portfolio of products, scale-up production and enter clinical trials.”
The Procarta approach ‘hacks’ the genetic code of the bacteria. First the bacteria DNA is sequenced and this is then used as a template to synthesise a new stretch of DNA code that can select which genes in the bacteria to turn off. This code forms the basis of a new antibiotic and Procarta has demonstrated that its technology is applicable to a range of bacteria.
Dr McArthur adds: “Using our platform technology new antibiotics can be designed rapidly by simple examination of the genome sequence. This would allow us to respond in a matter of weeks to outbreaks of dangerous and difficult to treat infections.
“This is a double pleasure: as the science grows so does the company and we will be recruiting. We want to play a key part of the scientific revolution that is going on at the Norwich Research Park.
“The UK government has backed us through its scientific funding body, the BBSRC, and there has always been an expectation that we will generate value and jobs; I am glad to reciprocate.”
The Norwich Research Park has one of the largest concentrations of microbiologists in Europe and this has created an exciting hub for drug discovery and research. It has particular strengths in the field of antimicrobials.
Collaboration across the Park – between the University of East Anglia (UEA), UEA’s Norwich Medical School, the Norfolk and Norwich University Hospital and the research institutes: The Genome Analysis Centre (TGAC), John Innes Centre (JIC) and the Institute of Food Research (IFR), plus a Clinical Trials Research Unit – has started to fast-track a range of new developments.
Some of these are aimed at the development of highly specific, narrow-spectrum antibiotics, which will benefit both patients and the societal management of infections.
• PHOTOGRAPH SHOWS: Dr Michael McArthur, co-founder and CSO of Procarta